

+ Evidence in focus

Interactive compendium of clinical evidence

POLAR3
Total Hip Solution

February 2024

Smith+Nephew



Key evidence

All evidence

.....

Product summaries

Interactivity has been included throughout the compendium to aid navigation

[Menu](#) will bring you back to this menu page

[All studies](#) will take you to a bibliography of all clinical evidence

Banners at the bottom of each page will take you to previous or subsequent pages, as indicated

Key evidence is represented in **blue** and supporting evidence in **brown**

THA — the "operation of the century"?

Due to recent technical and surgical advancements, THA is now one of the most cost-effective and consistently successful surgeries performed in orthopaedics^{1,2}

Important recent advances include:¹

Less invasive surgical procedures

Improved tissue preservation

Improved wear resistance and biocompatibility of biomaterials

Improved knowledge and restoration of hip anatomy and function

Reduced blood loss and surgical complications

Improved pre-operative management and post-operative pain control

THA provides reliable outcomes for patients with osteoarthritis, and excellent long-term postoperative clinical outcomes:²



Reduced pain²



Restored function²



Improved QoL²



National registries report excellent clinical outcomes, with 10-year survivorship rates of ~95% for uncemented THA



95.6%
(NJR)³



95.7%
(AOANJRR)⁴




95.4%
(LROI)⁵

Despite these positive outcomes, wide variety in the performance of different types of hip constructs remains and implant choices can result in considerable reductions in revision risk^{3,6}



UK NICE guidelines recommend that prostheses for THA in patients with end-stage arthritis should have revision rates (or projected rates) of 5% or less at 10 years⁷

However, the current NICE benchmark of 5% represents a 62% higher 10-year revision risk compared with top performing hip constructs on the market, which have revision rates as low as 1.9%^{3,6,7}



The risk and impact of revision — is there room for improvement?

Risk factors for revision

Several factors influence primary THA revision risk. Limitations of hip constructs combine with patient- and surgeon-related factors to contribute to overall risk^{3,4,8-13}



Aseptic loosening

(#1 reason for revision reported in the NJR)³

The proportion of revisions attributed to aseptic loosening ranges from 20.8% in the AOANJRR to 24.8% in the NJR^{3,4}

Higher revision rates due to loosening are associated with smaller cementless stems and certain variants of stem design^{9,10}




Dislocation

(#2 reason for revision reported in the NJR)³

The proportion of revisions attributed to dislocation ranges from 16.8% to 21.7% across registries^{3-5,11}

Implant positioning and different bearing materials can also contribute to overall revision risk^{8,14-22}



Implant positioning

Acetabular positioning can influence overall implant survival, joint stability, muscle function, range of motion, wear and functional outcomes¹⁴

Choice of bearing material

CoC

4x risk of implant fracture (vs MoXLPE)^{8,15}

Up to 30% incidence of implant noise^{8,16}

6x earlier time to revision due to dislocation relative to Metal on polyethylene (MoPE)¹⁷

CoXLPE

Fracture risk may remain with fourth generation ceramics¹⁸

Up to 33% risk of phase transformation^{19,20}

MoXLPE

67% higher volumetric wear (vs ceramicised metal)²¹

3.2% symptomatic mechanically assisted crevice corrosion (MACC) present²²

The risk and impact of revision — is there room for improvement?

Financial impact and patient satisfaction

Revision THA has considerable budgetary impacts for hospitals and can negatively affect care provision as a result²³

Compared to primary THA, revision THA is associated with increases in:




Operating time²³



Length of hospital stay (1.5x that of primary THA)^{23,24}



Blood loss²³



Re-revision risk (3x first revision risk)^{3,4}

This leads to increased treatment costs:



Revision THA is associated with 1.4x the cost of primary THA²⁵

Increased costs associated with revision THA may create budgetary pressures for hospital administrations and challenges in providing:




Access to care²⁶



High quality care²⁶

Evidence suggests that there is room for improvement in patient satisfaction following THA; lower satisfaction ratings are associated with a negative impact on patients, surgeons and providers^{8,27-30}



1 in 10 patients are not satisfied with their primary THA²⁷

This group of dissatisfied patients includes a subset who ultimately do not undergo revision^{8,28}

Low levels of patient satisfaction can have a range of negative effects:



Patients

Patients with poor function at 6 months are at higher risk of developing complications by 5 years²⁹



Surgeons

Increased litigation risk for surgeons versus patients with very good satisfaction ratings³⁰

19%



Providers

On average, 1 dissatisfied patient tells 11 people about their experience³⁰

Importance of implant choice

Improved survival rates are associated with choice of hip replacement, in addition to factors such as the skill of the surgeon and the setup of the hospital.¹ To achieve optimal survival results, the use of implants with evidence of good long-term survival should be encouraged⁶

POLAR3 is uniquely differentiated from other constructs. POLARSTEM[®]/R3[®] delivers the highest survivorship of any cementless hip combination,³ and with OXINIUM[®]/XLPE, it delivers superior PROMs and higher than class average patient satisfaction³¹

POLAR3 (POLARSTEM, OXINIUM/XLPE, R3 cup)

Survivorship

POLARSTEM/R3 delivers high survivorship compared with other cementless hip combinations³



POLARSTEM/R3 demonstrated survivorship of **98.1%** at 10 years³

This corresponds to a **62%** lower revision risk relative to the 5% NICE benchmark^{3,7}

POLAR3 results in significantly lower incidences of aseptic cup (67%; $p < 0.05$)³¹ and stem loosening (64%; $p < 0.05$)³¹




OXINIUM/XLPE delivers the highest survivorship of all bearing combinations in the UK, reducing concerns around revision risk with other bearing options¹⁵



OXINIUM/XLPE demonstrated survivorship of **98.04%** at 10 years¹⁵


This corresponds to a **60%** lower revision risk relative to the 5% NICE benchmark^{7,15}

OXINIUM/XLPE is also associated with a reduced risk of long-term complications, such as implant fracture, MACC and wear potential^{21, 32-37}




PROMs and patient satisfaction

POLAR3 is associated with significantly greater improvements in PROMs and higher than class average patient satisfaction when compared with other cementless combinations³¹



RI.HIP NAVIGATION

Hip navigation technology in THA improves the accuracy of acetabular component positioning, resulting in reduced risk of revision compared with conventional THA^{38,39}



Lowers revision risk by **55%** compared with conventional THA³⁹

RI.HIP NAVIGATION does not require a CT scan, limiting disruption of the standard patient pathway



National Joint Registry for England, Wales and Northern Ireland: POLARSTEM Cementless (Oxinium/XLPE/R3 cup) implant summary report. October 20, 2023³¹

Overview



Registry data*
Implant summary report



25,619 THAs with POLARSTEM[®]
588,183 THAs with other
uncemented stems

Assessed
at:



Survivorship



PROMs/Satisfaction

Results




At 11 years,
POLAR3
demonstrated
survivorship of
97.8%

Compared with the average for all other uncemented stems, POLAR3:


Was associated with
significantly **lower revision risk**
(38%; $p < 0.001$)[†]

Achieved significantly better
average patient 6-month **OHS**,
EQ-5D and **EQ-VAS** scores
($p < 0.001$)



Demonstrated that
patients are **significantly
more likely to be
satisfied with their THA**
at 6 months post-THA
($p < 0.001$)

Satisfaction[‡]



n=4,913 n=146,768


* NJR data recorded between 2007–2023.

[†] Unadjusted analysis. All results reported exclude metal-on-metal bearings.

[‡] Answer to 6-months general health question: How would you describe the results of your operation?

Conclusion

POLAR3 showed excellent 11-year survivorship and a significantly lower risk of revision compared to the average for other uncemented stems. At 6 months, patients reported higher satisfaction, increased hip functionality, and improved quality of life.



National Joint Registry for England, Wales and Northern Ireland: POLARSTEM Cementless implant summary report. November 8, 2023⁴⁰

Overview



Registry data
Implant summary report



32,499 THAs with POLARSTEM[®]
591,482 THAs with other
uncemented stems

Assessed at:



Survivorship



PROMs/Satisfaction

Results


Compared with the average for all other uncemented stems, POLARSTEM:



At 13 years,
POLARSTEM
demonstrated
survivorship of
95.9%


Was associated with
significantly **lower revision risk**
(38%; $p < 0.001$)*

Achieved significantly better
average patient 6-month **OHS**,
EQ-5D and **EQ-VAS** scores
($p < 0.001$)



Demonstrated that
patients are **significantly
more likely to be
satisfied with their THA**
at 6 months post-THA
($p < 0.001$)

Satisfaction[†]



n=6,554 n=146,767

*Unadjusted analysis. All results reported exclude metal-on-metal bearings.

†Answer to 6-months general health question: How would you describe the results of your operation?

Conclusion

POLARSTEM showed excellent 13-year survivorship and a significantly lower risk of revision compared to the average for other uncemented stems. At 6 months, patients reported higher satisfaction, increased hip functionality, and improved quality of life.



National Joint Registry for England, Wales and Northern Ireland: R3 Cementless cup implant summary report. November 8, 2023⁴¹

Overview



Registry data
Implant summary report



51,567 THAs with R3[®]
994,607 THAs with other
uncemented stems

Assessed
at:



Survivorship



PROMs/Satisfaction

Results



At 14 years, R3
demonstrated
survivorship of
97.1%

Compared with the average for all other uncemented stems, R3:


Was associated with
significantly **lower revision risk**
(27%; $p < 0.001$)^{*}

Achieved significantly better
average patient 6-month **OHS**,
EQ-5D and **EQ-VAS** scores
($p < 0.001$)



Demonstrated that
patients are **significantly
more likely to be
satisfied with their THA**
at 6 months post-THA
($p < 0.001$)

Satisfaction[†]



n=12,297 n=218,550

^{*}Unadjusted analysis. All results reported exclude metal-on-metal bearings.

[†]Answer to 6-months general health question: How would you describe the results of your operation?

Conclusion

R3 showed excellent 14-year survivorship and a significantly lower risk of revision compared to the average for other uncemented cups. At 6 months, patients reported higher satisfaction, increased hip functionality, and improved quality of life.



Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) Hip, Knee & Shoulder Arthroplasty: 2023 Annual Report⁴

Available at: <https://aoanjrr.sahmri.com/annual-reports-2023>. Accessed October 30, 2023.

Overview



Registry data
Annual report



34,564 THAs with OXINIUM[®]/XLPE
513,239 THAs with other bearing combinations

Assessed at:




**Survivorship/
Revision risk**

Results

Survivorship

Figure HT32 Cumulative Percent Revision of Primary Total Conventional Hip Replacement by Bearing Surface (Primary Diagnosis OA)



At 15 years, OXINIUM/XLPE had the lowest cumulative revision rate of all bearing combinations analysed (4.9%)

Comparing the rates of revision for these bearings, Ceramicised Metal/XLPE* has the lowest rate of revision at 15 years. As in previous years, the Registry urges caution in the interpretation of this result. This bearing is a single company product, used with a small number of femoral stem and acetabular component combinations. This may have a confounding effect on the outcome, making it unclear if the lower rate of revision is an effect of the bearing surface or reflects the limited combinations of femoral and acetabular prostheses. Tables and graphs have been reproduced in exact and complete form. *The term 'Ceramicised Metal/XLPE' is equivalent to 'OXINIUM/XLPE', and the term 'Non XLPE' is equivalent to 'CPE' reported on other slides.

Number at Risk	0 Yr	1 Yr	3 Yrs	5 Yrs	10 Yrs	15 Yrs	20 Yrs
Ceramic/Ceramic	103169	97040	86119	73169	36002	12218	1098
Ceramic/Non XLPE	9351	8401	6922	5591	3411	2044	543
Ceramic/XLPE	124435	104581	72045	45553	12319	2542	95
Metal/Metal >32mm	14422	14061	13215	11979	9280	2855	52
Metal/Metal ≤32mm	5143	5021	4840	4654	3902	2381	382
Metal/Non XLPE	35581	34223	31856	29125	20703	11024	1875
Metal/XLPE	186339	170870	143203	114213	48606	12591	457
Ceramicised Metal/XLPE	31411	27529	21695	16689	6590	1682	0

Note: Only bearing surfaces with >5,000 procedures have been listed

HR adjusted for age and gender

Ceramic/Ceramic vs Metal/XLPE	Entire Period: HR=1.00 (0.96, 1.04), p=0.978	Metal/Metal >32mm vs Metal/XLPE	0 - 2Wk: HR=1.29 (0.97, 1.71), p=0.080 2Wk - 3Mth: HR=0.64 (0.51, 0.80), p<0.001 3Mth - 9Mth: HR=1.14 (0.89, 1.46), p=0.297 9Mth - 1.5Yr: HR=2.71 (2.29, 3.21), p<0.001 1.5Yr - 2Yr: HR=4.21 (3.49, 5.06), p<0.001 2Yr - 3Yr: HR=6.59 (5.83, 7.44), p<0.001 3Yr - 6Yr: HR=10.36 (9.65, 11.11), p<0.001 6Yr - 9.5Yr: HR=6.98 (6.44, 7.58), p<0.001 9.5Yr - 10.5Yr: HR=6.03 (5.10, 7.13), p<0.001 10.5Yr+: HR=3.55 (3.21, 3.92), p<0.001
Ceramic/Non XLPE vs Metal/XLPE	0 - 3Mth: HR=1.01 (0.83, 1.24), p=0.900 3Mth - 2Yr: HR=1.41 (1.17, 1.69), p<0.001 2Yr+: HR=1.97 (1.78, 2.17), p<0.001	Ceramicised Metal/XLPE vs Metal/XLPE	0 - 3Mth: HR=1.23 (1.11, 1.36), p<0.001 3Mth+: HR=0.71 (0.65, 0.77), p<0.001
Ceramic/XLPE vs Metal/XLPE	0 - 2Wk: HR=1.08 (0.96, 1.23), p=0.192 2Wk - 1Mth: HR=1.04 (0.94, 1.15), p=0.470 1Mth - 1.5Yr: HR=1.02 (0.96, 1.09), p=0.539 1.5Yr+: HR=0.79 (0.74, 0.84), p<0.001		
Metal/Metal ≤32mm vs Metal/XLPE	Entire Period: HR=1.40 (1.27, 1.54), p<0.001		
Metal/Non XLPE vs Metal/XLPE	0 - 1Mth: HR=0.74 (0.63, 0.87), p<0.001 1Mth - 3Mth: HR=0.86 (0.72, 1.04), p=0.114 3Mth - 1.5Yr: HR=1.31 (1.17, 1.47), p<0.001 1.5Yr - 6.5Yr: HR=1.51 (1.40, 1.64), p<0.001 6.5Yr - 17.5Yr: HR=2.27 (2.13, 2.41), p<0.001 17.5Yr+: HR=2.42 (1.86, 3.14), p<0.001		

Conclusion

OXINIUM/XLPE was associated with excellent 15-year survivorship.



Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) Hip, Knee & Shoulder Arthroplasty: 2023 Annual Report⁴

Available at: <https://aoanjrr.sahmri.com/annual-reports-2023>. Accessed October 30, 2023.

Overview



Registry data
Annual report



34,564 THAs with OXINIUM[®]/XLPE
513,239 THAs with other bearing combinations

Assessed at:




**Survivorship/
Revision risk**

Results

Revision risk

Figure HT40 Cumulative Percent Revision of Primary Total Conventional Hip Replacement by Bearing Surface (Primary Diagnosis OA)



From 1 year, OXINIUM/XLPE demonstrates a significantly lower risk of revision compared to Metal/XLPE by 38% ($p < 0.001$)

Comparing the rates of revision for these bearings, Ceramicised Metal/XLPE* has the lowest rate of revision at 15 years. As in previous years, the Registry urges caution in the interpretation of this result. This bearing is a single company product, used with a small number of femoral stem and acetabular component combinations. This may have a confounding effect on the outcome, making it unclear if the lower rate of revision is an effect of the bearing surface or reflects the limited combinations of femoral and acetabular prostheses. Tables and graphs have been reproduced in exact and complete form. *The term 'Ceramicised Metal/XLPE' is equivalent to 'OXINIUM/XLPE', and the term 'Non XLPE' is equivalent to 'CPE' reported on other slides.

Number at Risk	0 Yr	1 Yr	3 Yrs	5 Yrs	10 Yrs	15 Yrs	20 Yrs
Ceramic/Ceramic	107126	101283	90732	78607	41948	14629	2623
Ceramic/Non XLPE	9962	9108	7463	6050	3541	2150	784
Ceramic/XLPE	143653	122064	86968	56755	15458	3377	286
Metal/Metal >32mm	14424	14063	13216	11981	9306	4165	100
Metal/Metal ≤32mm	5143	5021	4840	4654	3954	2651	787
Metal/Non XLPE	35807	34413	32041	29306	20949	11722	3369
Metal/XLPE	196515	181105	153647	124529	56134	15691	1385
Ceramicised Metal/XLPE	34564	30720	24139	18672	8012	2230	0

Note: Only bearing surfaces with >5,000 procedures have been listed

HR – adjusted for age and gender

Ceramic/Ceramic vs Metal/XLPE
Entire Period: HR=0.99 (0.96, 1.03), $p=0.770$

Ceramic/Non XLPE vs Metal/XLPE
0 - 2Yr: HR=1.16 (1.01, 1.32), $p=0.029$
2Yr - 3.5Yr: HR=1.48 (1.15, 1.91), $p=0.002$
3.5Yr - 5Yr: HR=0.85 (0.58, 1.24), $p=0.388$
5Yr - 8Yr: HR=1.50 (1.18, 1.89), $p<0.001$
8Yr+: HR=2.67 (2.37, 3.01), $p<0.001$

Ceramic/XLPE vs Metal/XLPE
0 - 2Yr: HR=1.01 (0.97, 1.06), $p=0.562$
2Yr+: HR=0.77 (0.72, 0.82), $p<0.001$

Metal/Metal >32mm vs Metal/XLPE
0 - 2Wk: HR=1.27 (0.96, 1.68), $p=0.092$
2Wk - 1Mth: HR=0.46 (0.31, 0.67), $p<0.001$
1Mth - 9Mth: HR=0.96 (0.79, 1.15), $p=0.636$
9Mth - 1.5Yr: HR=2.81 (2.38, 3.33), $p<0.001$
1.5Yr - 2Yr: HR=4.40 (3.66, 5.29), $p<0.001$
2Yr - 3Yr: HR=6.46 (5.72, 7.29), $p<0.001$
3Yr - 8Yr: HR=9.45 (8.90, 10.02), $p<0.001$
8Yr - 10Yr: HR=5.92 (5.28, 6.63), $p<0.001$
10Yr - 12Yr: HR=4.86 (4.29, 5.51), $p<0.001$
12Yr+: HR=3.35 (2.97, 3.77), $p<0.001$

Metal/Metal ≤32mm vs Metal/XLPE
Entire Period: HR=1.42 (1.30, 1.56), $p<0.001$

Metal/Non XLPE vs Metal/XLPE
0 - 1Mth: HR=0.73 (0.62, 0.85), $p<0.001$
1Mth - 6Mth: HR=0.89 (0.77, 1.03), $p=0.120$
6Mth - 3.5Yr: HR=1.41 (1.30, 1.54), $p<0.001$
3.5Yr - 5Yr: HR=1.57 (1.36, 1.80), $p<0.001$
5Yr - 7Yr: HR=1.73 (1.53, 1.96), $p<0.001$
7Yr - 10Yr: HR=2.13 (1.93, 2.37), $p<0.001$
10Yr+: HR=2.56 (2.38, 2.76), $p<0.001$

Ceramicised Metal/XLPE vs Metal/XLPE
0 - 6Mth: HR=1.16 (1.06, 1.27), $p=0.001$
6Mth - 1Yr: HR=1.04 (0.85, 1.28), $p=0.694$
1Yr+: HR=0.62 (0.56, 0.69), $p<0.001$

Conclusion

OXINIUM/XLPE was associated with the lowest risk of revision of all bearing combinations analysed.



National Joint Registry for England, Wales and Northern Ireland: 20th Annual Report³

Available at: <https://reports.njrcentre.org.uk>. Accessed December 8, 2023.

Overview



Registry data*
Annual report



27,529 THAs with POLARSTEM[®]/R3[®]
536,411 THAs with all uncemented
stem/cup combinations

Assessed at:



**Survivorship/
Revision risk**

Results



1.93%

POLARSTEM with R3 was associated with a 1.93% revision rate at 10 years, one of the lowest among all uncemented hip prostheses

This corresponds to a 57% reduction in revision risk compared with the class average revision rate for the NJR




Figure. Cumulative revision of THA prostheses with at least 10 years follow-up and ≥10,000 procedures and >250 implants at risk

*NJR data recorded between 2003–2023.

Conclusion

POLARSTEM with R3 demonstrates one of the highest survivorship rates of all uncemented hip constructs at 10 years, with a 1.93% revision rate.



Long-term outcomes of a dual-mobility cup and cementless triple-taper femoral stem combination in total hip replacement: a multicenter retrospective analysis⁴²

Cypres A, Fiquet A, Girardin P, et al. *J Orthop Surg Res.* 2019;14:376.

Overview



Clinical study

Multicentre,
retrospective analysis



244 THAs with POLARSTEM[®] and
POLARCUP[®]

Assessed at:



**Survivorship/
PROMs**

Results

Survivorship



At a mean follow-up of 11.9 years, POLARSTEM had a cumulative 10-year all-cause survivorship of

99.1%

Radiographic analysis




Radiographic analysis revealed no cases of stem subsidence (0%) or bone hypertrophy (0%), one case of bone atrophy (0.4%) and three cases of osteolysis around the stem (1.2%)

PROMs

At 10 years' follow-up, patients also reported WOMAC scores in the satisfactory range


WOMAC Score




Stiffness



Function



Pain



Conclusion

POLARSTEM was associated with excellent 10-year survivorship along with strong radiographic outcomes, and patients that received this implant reported satisfactory WOMAC scores at 10 years of follow-up.



Excellent mid-term outcomes with a hemispheric titanium porous-coated acetabular component for total hip arthroplasty: 7–10 year follow-up⁴³

Yeroushalmi D, Singh V, Maher N, Gabor JA, Zuckerman JD, Schwarzkopf R. *Hip Int.* 2021 Aug 19. doi: 10.1177/11207000211040181.

Overview



Clinical study

Single centre,
retrospective analysis



118 THAs (114 primary; 4 revision)
with R3[®]

Assessed at:



**Kaplan-Meier
survivorship**

Results

Survivorship

R3 demonstrated
excellent survivorship
at 10 years' follow-up



Survivorship

99.1%

Aseptic acetabular
revision rate


0%

Safety

At latest follow-up (mean: 8.19 years), R3 was also associated with no radiographic and limited clinical complications, including:



No cases of
osteolysis
(0%)



No cases of
cup migration
(0%)



Low rate of
postoperative
complications (2.5%)

Conclusion

R3 was associated with excellent mid-term survivorship and clinical outcomes, with no radiologically observed cup migration or osteolysis and very low postoperative complication rates.



Effect of bearing surface on survival of cementless and hybrid total hip arthroplasty¹⁵

Davis ET, Pagkalos J, Kopjar B. *JBJS OA*. 2020;5:e0075.

Overview



Registry analysis*



9,237 THAs with Ceramicised Metal/XLPE[†]

411,102 THAs with other bearing combinations

Assessed at:




**Survivorship/
Revision risk**

Results

OXINIUM[®]/XLPE demonstrated a revision risk of 1.96% at 10 years in the full patient population, the lowest of all bearing combinations

1.96%

OXINIUM/XLPE also demonstrated the lowest risk of revision of all bearing combinations in patients aged <55 years (1.80%)



* NJR data recorded between 2004–2016.

†The term 'Ceramicised Metal/XLPE' is equivalent to 'OXINIUM/XLPE' reported on other slides.

Conclusion

OXINIUM/XLPE was associated with the lowest revision risk at 10 years (1.96%) of all bearing combinations analysed.



Mid-term clinical results of the cementless R3 cup and Polarstem total hip arthroplasty⁴⁴

Assaf A, Manara JR, Teoh KH, Evans AR. *Eur J Orthop Surg Traumatol.* 2019;29:827–833.

Overview



Clinical data
Single-centre study



114 THAs
with POLARSTEM[◊]/R3[◊]

Assessed at:



Results

At 7 years' follow-up, POLARSTEM/R3 was associated with:

A cumulative all-cause survivorship of 97.69%

A mean OHS of 38 (range: 8–48, with 8 being the worst and 48 the best)

No radiolucency around the femoral stem, and no evidence of osteolysis of R3 cups



Conclusion

POLARSTEM with R3 demonstrated excellent mid-term outcomes after 7 years, with high cumulative survivorship, as well as good radiographic and patient-reported functional outcomes.



The effect of bearing type on the outcome of total hip arthroplasty⁴⁵

Peters RM, Van Steenberghe LN, Stevens M, Rijk PC, Bulstra SK, Zijlstra WP. *Acta Orthop*. 2018;89;163–169.

Overview



Dutch registry analysis*



11,785 THAs
with OXINIUM[®]/XLPE or
OXINIUM/PE bearings

Assessed at:



Results

When compared with MoPE, MoXLPE, CoPE, CoXLPE, and CoC, OXINIUM/(XL)PE[†] resulted in:

The highest all-cause survivorship at 5 (97.5%) and 9 years (96.5%)



When compared with Metal/PE bearings, OXINIUM/(XL)PE* was associated with:

A 19% lower risk of revision (p<0.05)



* Registry data recorded between 2007–2016.

† Due to small group sizes, OXINIUM on standard PE or XLPE were analysed together, with results for OXINIUM/(XL)PE representing grouped data for OXINIUM bearings on XLPE or PE.

Conclusion

OXINIUM/(XL)PE demonstrated the highest 5- and 9-year survivorship when compared with several other bearing types, and a significantly lower revision risk when compared with Metal/PE bearings.



Can the choice of cementless implants and bearings during total hip arthroplasty have an impact on the overall costs within a bundled payment model?⁴⁶

Duncan S, Patel A, Delhougne G, Patrick C. *J Hip Surg.* 2020;4:66–76.

Overview




Health economic data
Retrospective US
database analysis



818 THAs with POLARSTEM[®]/R3[®] and
OXINIUM[®] bearing;
2,454 THAs with other cementless hip
systems and ceramic bearings

Analysis included
THAs performed
between:



Results

When compared with non-OXINIUM bearings, THA with OXINIUM bearings was associated with:

Significantly lower mean LOS (1.61 vs 2.06 days, respectively; $p < 0.0001$) and 30-day readmission rate (1.88 vs 3.31%; $p = 0.0399$)



A small increase (4%) in mean hospital costs (\$15,611 vs \$15,002; $p = 0.0039$)



A significantly greater likelihood for patients to be discharged to home/home health care (OR: 1.36; 95% CI: 1.07, 1.72; $p = 0.0112$), and a lower likelihood of patients being discharged to an SNF (OR: 0.82; 95% CI: 0.63, 1.06; $p = 0.1235$)



A significantly lower likelihood of patients requiring a blood transfusion (OR: 0.16; 95% CI: 0.09, 0.29; $p < 0.0001$)



Conclusion

THA with POLARSTEM/R3 and OXINIUM bearings was associated with improved short-term clinical outcomes relative to other cementless hip systems with ceramic bearings. Reduced LOS and lower rates of discharge to SNF may result in cost savings overall in bundled payment systems despite a small increase in total hospital costs.



Functional and radiological outcome of uncemented total hip arthroplasty in young adults — 5 year follow-up⁴⁷

Wade R, Shah KA. *J Orthop*. 2019;18:237–239.

Overview



Clinical data
Single-centre study



56 THAs
with POLARSTEM[®]/R3[®]/
OXINIUM[®]/XLPE*

Assessed at:



Results

At 5 years' follow-up, in patients <40 years, POLAR3 was associated with:

Improved mean HHS versus preoperative scores (92 vs 36, respectively), with a high proportion of patients able to carry out 'strenuous' or 'moderate' manual labour (80%)



No major postoperative complications




No femoral or acetabular component loosening, and neutral femoral stem alignment in the majority (82%) of hips



*Most common arthritis aetiology: avascular hip necrosis (57%). Other aetiologies included post-traumatic arthritis (21%), ankylosing spondylitis (16%) and rheumatoid arthritis (7%).

Conclusion

THA with POLAR3 delivers strong medium-term functional and radiological outcomes in younger patients, and low complication rates.



A comparative study between uncemented and hybrid total hip arthroplasty in octogenarians⁴⁸

Ahmad A, Mirza Y, Evans AR, Teoh KH. *J. Arthroplasty*. 2018;33:3719–3723.

Overview



Clinical data

Single-centre study of octogenarians (mean age: 86.2 years)



143 THAs (76 with POLARSTEM[®]/R3[®]; 67 with hybrid [Exeter* cemented stem/Trilogy Cup[†]])

Assessed at:



Revision risk/
PROMs

Results

Compared with hybrid THA, THA with POLARSTEM/R3 was associated with:

Significantly lower intraoperative complication (p=0.017) and transfusion (p=0.002) rates



No significant difference in average hospital stay (11 vs 12 days; p=0.27)



Similar revision rates (two revisions in each cohort)



A similar degree of improvement in mean OHS from preoperative scores to final follow-up (22 to 40 vs 24 to 38, respectively)



*Exeter cemented stem is a trademark of Stryker. [†]Trilogy Cup is a trademark of Zimmer.

Conclusion

POLARSTEM with R3 delivers safety comparable to hybrid THA for elderly patients, with lower complication and transfusion rates, and similar revision rates.



Acetabular liner dissociation: a comparative study of two contemporary uncemented acetabular components⁴⁹

Gwynne-Jones DP, Memon A. *Arthroplast Today*. 2020;6:354–359.

Overview



Clinical data

Single-centre, retrospective, comparative study



961 THAs

(426 with R3[®]/XLPE;
535 with Pinnacle[®]/Marathon)

Assessed at:



Results

At 7 years' follow-up, when compared with the Pinnacle acetabular component, R3 demonstrated:

Significantly higher all-cause survivorship (99.0 vs 96.1%; $p=0.022$)

A significantly lower liner dissociation rate (0 vs 1.12%; $p=0.038$)



*Pinnacle is a trademark of Depuy Synthes.

Conclusion

R3 was associated with higher 7-year survivorship and lower rates of revision and liner dissociation, when compared with the Pinnacle acetabular component.



R3 cup does not have a high failure rate in conventional bearings: a minimum of 5-year follow-up⁵⁰

Teoh KH, Whitham RDJ, Golding DM, Wong JF, Lee PYF, Evans AR. *J Arthroplasty*. 2018;33:460–463.

Overview



Clinical data
Single-centre,
retrospective analysis



293 THAs
(**283** with POLARSTEM[®]/R3[®];
10 with hybrid)

Assessed at:



Results

At 5 years' follow-up, R3 was associated with:

A survivorship of 98.9%



An improvement in mean OHS versus preoperative scores (40 vs 23, respectively)



Excellent Agora Radiographic Assessment scores in all patients and no evidence of osteolysis of R3 cups



Conclusion

R3 was associated with excellent clinical and radiographic outcomes at 5 years postoperatively, including high survivorship.



Retrospective analysis of oxidized zirconium bearing surface in hip replacement 90-day episode claims⁵¹

Patrick C, Delhougne G, Patel AR. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR); May 18–22, 2019; New Orleans, Los Angeles, USA.

Overview



Clinical and health economic data
Retrospective US database analysis



818 THAs with POLARSTEM[®]/R3[®] and OXINIUM[®] bearing;
2,454 THAs with other cementless hip systems and non-OXINIUM bearings

Analysis included THAs performed over three consecutive quarters



Results

When compared with non-OXINIUM bearings, THA with OXINIUM bearings was associated with:

A lower revision rate in the first 90-days post-surgery (0.9 vs 1.4%; p=0.110)



Significantly lower costs per 90-day episode of care (\$18,364 vs \$18,966; p=0.003)



Lower rates of 30- and 90-day all-cause readmissions (21.3 and 12.7% relative reductions, respectively; p>0.05)



A significant 15.9% relative reduction in rate of discharge to SNFs (p=0.002)



Conclusion

When compared with non-OXINIUM bearings, THA with OXINIUM bearings was associated with a lower average cost per 90-day episode of care that was attributed to reductions in the use of SNFs and hospital readmission.



Minimizing complications in bikini incision direct anterior approach total hip arthroplasty: a single surgeon series of 865 cases⁵²

Alva A, Nizam I, Gogos S. *J Exp Orthop*. 2021;8:1.

Overview



Clinical data

Single surgeon case series



865 cases of bikini incision DAA THA using POLARSTEM[®]/CPCS stem with R3[®] and OXINIUM[®]

Assessed at:



Results

At final follow-up (mean: 3.9 years), when used in bikini incision DAA THA, POLARSTEM/CPCS stems with R3 and OXINIUM were associated with:

A survivorship of 99.84% and 99.53% for the cup and stem components, respectively



Low complication rates, ranging from 0 to 6.4% dependent on specific complication



Improvements in mean HHS and WOMAC score from preoperative to postoperative measurements (HHS: 53 to 92.5; WOMAC score: 49 to 3.5)



Conclusion

POLARSTEM with R3 and OXINIUM can be safely used to perform bikini incision DAA THA, demonstrating high survivorship at a mean follow-up of 3.9 years, low rates of intraoperative and postoperative complications and improvements in PROMs.



Excellent midterm survival and functional outcomes of a fully hydroxyapatite-coated cementless stem: first results of a prospective multicenter study⁵³

Willburger RE, Heukamp M, Lindenlauv TE, Peterlein CD, Schuttler KF. *Arthroplast Today*. 2020;6:201–205.

Overview



Clinical data

Prospective, multicentre, observational study



225 THAs with POLARSTEM[®]

Assessed at:



Results

At 5 years' follow-up, POLARSTEM was associated with:

Excellent survivorship of 99.6%



A low rate of intraoperative complications (1.3%)



Significant improvements in mean HHS and WOMAC score from baseline to postoperative measurements (HHS: 48.5 to 88.0, $p < 0.01$; WOMAC score: 58.6 to 9.3; $p < 0.01$)



Conclusion

POLARSTEM was associated with excellent clinical outcomes, including high medium-term survivorship, low rates of intraoperative complications, and significant improvements in PROMs.



Midterm results of a contemporary, porous-coated acetabular system in patients undergoing primary total hip replacement for degenerative hip disease: a prospective, multicenter study⁵⁴

Wilson AI, Turgeon TR, Gascoyne RW, Della Valle CJ, McCalden RW. *J Arthroplasty*. 2020;35:1862–1867.

Overview



Clinical data

Prospective,
multicentre, study



155 THAs using R3[®] with
different liners (**132** XLPE;
21 ceramic; **2** metal)

Assessed at:



Results

At 5 years' follow-up, R3 was associated with:

A survivorship of 97.1%, with no significant difference in survival between polyethylene and ceramic liners used ($p=0.55$)

Significant improvements in mean HHS and WOMAC score from preoperative to postoperative measurements (HHS: 51.4 to 94.5, $p<0.001$; WOMAC score: 40.9 to 89.1; $p<0.001$)



Conclusion

R3 was associated with excellent clinical outcomes and improvements in patient report outcomes, when used with both XLPE and ceramic liners.



2-year radiostereometric analysis evaluation of a short, proximally coated, triple-taper blade femoral stem versus a quadrangular-taper stem with reinforced proximal body: a randomized controlled trial⁵⁶

Fontalis A, Kayani B, Vanhegan I, et al. *J Arthroplasty*. 2023;38(7S):S152–S161.

Overview



Clinical data

Prospective, single-centre
UK RCT



29 THAs with POLAR3[®];
27 with TriFit TS femoral stem/
Trinity acetabular shell*

Assessed at:



Results

At 2 years' follow-up, when compared with the TriFit TS femoral stem and Trinity acetabular shell component, POLAR3 demonstrated:

Improvements in PROMs and EQ-5D results compared to preoperative scores


Significantly less total migration at 6 months ($p=0.018$), 1 year ($p=0.007$) and 2 years ($p=0.030$)



*TriFit TS and Trinity are trademark of Corin.

Conclusion

In a UK RCT, RSA analysis showed improved total migration results for POLAR3 compared to the TriFit TS femoral stem/Trinity acetabular shell. These results suggest the stems are likely to achieve long-term stability and clinical longevity.



Comparison of canal fill and radiolucent line formation between two fully coated, hydroxyapatite tapered stems: a 2-year follow-up after total hip arthroplasty⁵⁷

Shichman I, Lawrence KW, Berzolla E, et al. *Orthop Trauma Surg.* 2023;143:6945–6954.

Overview



Clinical data

Retrospective,
multicentre, observational
study



132 THAs with POLARSTEM[®];
101 THAs with CORAIL*

Assessed at:



Results

At 2 years' follow-up, when compared with the CORAIL femoral stem, POLARSTEM demonstrated:

Significantly greater average femoral stem canal fill in the middle third of the stem ($p=0.002$)

Comparable low rates of subsidence and low rates of radiolucent line formation



*CORAIL is a trademark of DePuy Synthes.

Conclusion

POLARSTEM demonstrated improved femoral canal fill in the middle third of the stem as well as comparable short-term survivorship when compared to the CORAIL femoral stem in this independent study.



Fully hydroxyapatite-coated compaction broached and triple-tapered stem may reduce the risk of stress shielding after primary total hip arthroplasty⁵⁸

Kuroda, Y, Hashimoto, S, Hayashi, S, et al. *Arch Orthop Trauma Surg.* 2022;142:4087–4093.

Overview



Clinical data

Retrospective cohort study



38 THAs with POLARSTEM[®];
31 THAs with HA-coated ANTHOLOGY[®]; **31 THAs** with non-HA-coated ANTHOLOGY

Assessed at:



Results

At 2 years' follow-up, when compared to ANTHOLOGY tapered-wedge stems, POLARSTEM demonstrated


Significantly lower incidence of stress shielding ($p=0.007$)

Significantly higher BMD around femoral calcar (Zone 7; $p=0.009$)



Conclusion


In this independent study, POLARSTEM maintained BMD around the femoral calcar at 2 years post-operatively and its use could reduce the risk of stress shielding when compared with tapered-wedge stems.



Product summary: **POLARSTEM[◇]**


9 studies reporting on POLARSTEM

POLARSTEM delivers excellent short- to mid-term survivorship



ODEP 10A*
POLARSTEM
uncemented stem⁵⁵

POLARSTEM demonstrates excellent clinical outcomes




POLARSTEM results in improved PROMs and patient satisfaction


POLARSTEM results in significantly improved average 6-month OHS, EQ-5D and EQ-VAS scores compared with other uncemented stems ($p < 0.001$),⁴⁰ and improvements from pre- to postoperative HHS and WOMAC scores^{42,53}



Patients who reported feeling much better/a little better post-THA⁴⁰



Patients who rated their post-THA satisfaction as 'excellent/very good'⁴⁰




■ POLARSTEM ■ Other uncemented stems



Product summary: R3[®]

8 studies reporting on R3

R3 delivers excellent short- to mid-term survivorship




R3 results in improved PROMs and patient satisfaction

R3 results in significantly improved average 6-month OHS, EQ-5D and EQ-VAS scores compared with other uncemented cups ($p < 0.001$),⁴¹ and improvements from pre- to postoperative HHS and WOMAC scores^{47,54}




Patients who reported feeling much better/a little better post-THA⁴¹




■ R3 ■ Other uncemented cups

Patients who rated their post-THA satisfaction as 'excellent/very good'⁴¹



R3 demonstrates excellent clinical outcomes



ODEP 13A*
R3
uncemented cup⁵⁵

1.4% lower cumulative 14-year revision rate compared with all other uncemented cups⁴¹




Product summary: OXINIUM[®]/XLPE

6 studies reporting on OXINIUM/XPLE


OXINIUM/XLPE demonstrates superior mid- to long-term survivorship compared with other bearing combinations

Highest survivorship of all bearing combinations analysed across multiple registries (AOANJRR; NJR; LRO)^{4,15,45}





OXINIUM/XLPE is associated with:

- A **38%** lower revision risk from 1 year compared with Metal/XLPE⁴
- A **19%** lower revision risk compared with Metal/PE⁴⁵
- A **60%** lower risk of revision relative to the 5% NICE benchmark (1.96%) at 10 years^{7,15}



OXINIUM/XLPE results in superior clinical and health economic outcomes compared with non-OXINIUM bearings




*OXINIUM/(XL)PE includes grouped data for OXINIUM bearings on XLPE or PE.




Product summary: **POLAR3**

5 studies reporting on POLAR3


POLAR3 delivers excellent short- to mid-term survivorship



POLAR3 is associated with strong clinical, functional and radiological outcomes







POLAR3 results in excellent PROMs and better than class average patient satisfaction



*This study included 865 cases of bikini incision DAA THA using POLARSTEM[®]/CPCS[®] stem with R3 and OXINIUM[®].





All clinical evidence

Select the icon to see the evidence overview.
References in bold and [blue](#) represent key evidence.

Author	Study summary	   			
		POLARSTEM [◇]	R3 [◇]	OXINIUM [◇] /XLPE	POLAR3
Ahmad A, et al. 2018	A comparative study between uncemented and hybrid total hip arthroplasty in octogenarians	✓	✓		
Alva A, et al. 2018	Minimising complications in bikini incision direct anterior approach total hip arthroplasty: a single surgeon series of 865 cases				✓
Assaf A, et al. 2019	Mid-term clinical results of the cementless R3 cup and Polarstem total hip arthroplasty	✓	✓		
AOANJRR annual report 2023	Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty: 2022 Annual Report			✓	
Cypres A, et al. 2019	Long-term outcomes of a dual-mobility cup and cementless triple-taper femoral stem combination in total hip replacement: a multicenter retrospective analysis	✓			
Davis ET, et al. 2020	Bearing surface and survival of cementless and hybrid total hip arthroplasty in the National Joint Registry of England, Wales, Northern Ireland and the Isle of Man			✓	
Duncan S, et al. 2020	Can the choice of cementless implants and bearings during total hip arthroplasty have an impact on the overall costs within a bundled payment model?				✓

All clinical evidence

Select the icon to see the evidence overview.
References in bold and [blue](#) represent key evidence.

Author	Study summary	   			
		POLARSTEM [◇]	R3 [◇]	OXINIUM [◇] /XLPE	POLAR3
Fontalis A, et al. 2023	2-year radiostereometric analysis evaluation of a short, proximally coated, triple-taper blade femoral stem versus a quadrangular-taper stem with reinforced proximal body: a randomized controlled trial				✓
Gwynne-Jones D and Memon A. 2020	Acetabular liner dissociation: A comparative study of two contemporary uncemented acetabular components	✓	✓		
Kuroda Y, et al. 2022	Fully hydroxyapatite-coated compaction broached and triple-tapered stem may reduce the risk of stress shielding after primary total hip arthroplasty	✓			
NJR implant summary report 2023	National Joint Registry for England, Wales and Northern Ireland: POLARSTEM Cementless (Oxinium/XLPE/R3 cup) implant summary report. 20 October 2023	✓	✓	✓	
NJR implant summary report 2023	National Joint Registry for England, Wales and Northern Ireland: POLARSTEM Cementless implant summary report. 8 November 2023	✓			
NJR implant summary report 2023	National Joint Registry for England, Wales and Northern Ireland: R3 Cementless cup implant summary report. 8 November 2023		✓		

All clinical evidence

Select the icon to see the evidence overview.
References in bold and [blue](#) represent key evidence.

Author	Study summary	POLARSTEM [◇]	R3 [◇]	OXINIUM [◇] /XLPE	POLAR3
Patrick C, et al. 2019	Retrospective analysis of oxidized zirconium bearing surface in hip replacement 90-day episode claims				
Peters RM, et al. 2018	The effect of bearing type on the outcome of total hip arthroplasty			✓	
Shichman I, et al. 2023	Comparison of canal fill and radiolucent line formation between two fully coated, hydroxyapatite tapered stems: a 2-year follow-up after total hip arthroplasty	✓			
Teoh KH, et al. 2018	R3 cup does not have a high failure rate in conventional bearings: a minimum of 5-year follow-up	✓	✓		
Wade R and Shah KA. 2019	Functional and radiological outcome of uncemented total hip arthroplasty in young adults - 5 year follow-up				✓
Willburger RE, et al. 2020	Excellent midterm survival and functional outcomes of a fully hydroxyapatite-coated cementless stem: first results of a prospective multicenter study	✓			
Wilson AI, et al. 2020	Midterm results of a contemporary, porous-coated acetabular system in patients undergoing primary total hip replacement for degenerative hip disease: a prospective, multicenter study		✓		
Yeroushalmi D, et al. 2021	Excellent mid-term outcomes with a hemispheric titanium porous-coated acetabular component for total hip arthroplasty: 7–10 year follow-up		✓		

References

1. Zagra L. Advances in hip arthroplasty surgery: what is justified. *EFORT Open Rev.* 2017;2:171–178.
2. Varacallo M, Luo TD, Johanson NA. Total Hip Arthroplasty Techniques. Treasure Island, FL: StatPearls Publishing; 2021.
3. National Joint Registry for England, Wales and Northern Ireland. 20th Annual Report, 2023. Available at: <https://reports.njrcentre.org.uk>. Accessed December 8, 2023.
4. Australian Orthopaedic Association National Joint Replacement Registry Hip, Knee & Shoulder Arthroplasty: 2023 Annual Report. Available at: <https://aoanjrr.sahmri.com/annual-reports-2023>. Accessed October 24, 2023.
5. Dutch Arthroplasty Register (LROI). Online LROI annual report (2023). Available at: <https://www.lroi-report.nl/hip>. Accessed December 8, 2023.
6. Evans JT, Blom AW, Timperley AJ, Dieppe P, Wilson MJ, Sayers A, et al. Factors associated with implant survival following total hip replacement surgery: A registry study of data from the National Joint Registry of England, Wales, Northern Ireland and the Isle of Man. *PLoS Med.* 2020;17: e1003291.
7. National Institute for Health and Care Excellence (NICE). Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip. Available at: <https://pathways.nice.org.uk/pathways/joint-replacement/hip-replacement#content=view-node%3Anodes-surgical-procedures>. Accessed November 11, 2021.
8. Smith & Nephew, Inc. EA_RECON_POLAR3_007_v1 SLR. Internal report. December 2020.
9. van der Jagt DR, Brekon A, Mokete L, Pietrzak J, Nortje M, Schepers A. Fixed prostheses can be loose: High hydroxyapatite loosening rates in the collarless corail uncemented stem. *Orthopaedic Proceedings.* 2018; 100-B(S11) S11.
10. Hoskins W, Bingham R, Lorimer M, de Steiger R. The effect of size for a hydroxyapatite-coated cementless implant on component revision in total hip arthroplasty: an analysis of 41,265 Stems. *J Arthroplasty.* 2020; 35(4):1074–1078.
11. Ciccarelli P, Urakcheeva I, Biondi A and Torre M. Italian Arthroplasty Registry. Annual Report 2021 — Addendum. Roma: Il Pensiero Scientifico Editore. 2022. Available at: <http://riap.iss.it/>. Accessed December 8, 2023.
12. Vigdorchik JM, Sharma AK, Elbuluk AM, Carroll KM, Mayman DJ, Lieberman JR. High offset stems are protective of dislocation in high-risk total hip arthroplasty. *J Arthroplasty.* 2020;36:210–216.
13. Memon AR, Gwynne-Jones D. Polyethylene liner dissociation with the Pinnacle acetabular component: should we be concerned. *Arthroplasty Today.* 2020;6:5–8.
14. Bhaskar D, Rajpura A, Board T. Current concepts in acetabular positioning in total hip arthroplasty. *Indian J Orthop.* 2017;51:386–396.
15. Davis ET, Pagkalos J, Kopjar B. Effect of bearing surface on survival of cementless and hybrid total hip arthroplasty. *JBJS OA.* 2020;5:e0075.
16. McDonnell S, Boyce G, Bare J, Young D, Shimmin A. The incidence of noise generation arising from the large-diameter Delta Motion ceramic total hip bearing. *Bone Joint J.* 2013;95-B(2):160–165.
17. Migaud H, Putman S, Kern G, et al. Do the reasons for ceramic-on-ceramic revisions differ from other bearings in total hip arthroplasty? *Clin Orthop Relat Res.* 2016;474:2190–2199.
18. Rankin CS, Robinson PG, Beattie N, Gaston P. Fracture of a BIOLOX Delta ceramic femoral head: a case report and update of the literature. *JBJS Case Connect.* 2019;9:e0336.
19. Parkes M, Sayer K, Goldhofer M, Cann P, Walter W, Jeffers J. Monoclinic transformation in BIOLOX DELTA ceramic hip retrievals. *Orthopaedic Proceedings.* 2018; 99-B(5).
20. Roy M, Noel O, Whiteside L. Phase transformation and roughening in artificially aged and retrieved zirconia-toughened alumina femoral heads. *J Arthroplasty.* 2019;34:772–780.
21. Parikh A, Hill P, Pawar V, Sprague J. Long-term simulator wear performance of an advanced bearing technology for TTHA. Poster presented at ORS 2013 Annual Meeting; January 26–29, 2013; San Antonio, Texas, USA.
22. Hussey DK, McGrory BJ. Ten-year cross-sectional study of mechanically assisted crevice corrosion in 1352 consecutive patients with metal-on-polyethylene total hip arthroplasty. *J Arthroplasty.* 2017;32:2546–2551.
23. Vanhegan IS, Malik AK, Jayakumar P, Ul Islam S, Haddad FS. A financial analysis of revision hip arthroplasty: the economic burden in relation to the national tariff. *J Bone Joint Surg Br.* 2012;94:619–623.
24. Hasenauer MD. How to develop a fair revision arthroplasty bundle: using perioperative complications and readmissions to investigate. *J Arthroplasty.* 2020;35:3427–3431.
25. Klouche S, Sariali E, Mamoudy P. Total hip arthroplasty revision due to infection: A cost analysis approach. *Orthop Traumatol Surg Res.* 2010; 96:124–132.
26. Schwierz C. Cost-containment policies in hospital expenditure in the European Union. European Commission, 2016. Available at: https://ec.europa.eu/info/sites/info/files/dp037_en.pdf. March 25, 2022.
27. Davis E, Saunders C. Patient satisfaction after primary total hip arthroplasty: can the bar be raised? A systematic literature and meta-analysis. Poster presented at: 2nd World Arthroplasty Congress; April 19–21, 2018; Rome, Italy.
28. Rolfson O, Karrholm J, Dahlberg LE, Garellick G. Patient-reported outcomes in the Swedish Hip Arthroplasty Register. *J Bone Joint Surg.* 2011; 93-B(7).
29. Watson BS, Jenkins PJ, Ballantyne JA. The natural history of unexplained early poor function following total hip replacement. *Int Orthop.* 2014;38:33–37.
30. Physicians Weekly. The true cost of alienating patients. Available at: <https://www.physiciansweekly.com/alienating-patients-cost>. Accessed November 8, 2021.
31. National Joint Registry for England, Wales and Northern Ireland: Polarstem Cementless (Oxinium/XLPE/R3 cup) implant summary report. 20 October 2023. Copy available from Smith & Nephew on request.
32. Leto A, Zhu W, Matsubara M, Pezzotti G. Bioinertness and fracture toughness evaluation of the monoclinic zirconia surface film of OXINIUM femoral head by Raman and cathodoluminescence spectroscopy. *J Mech Behav Biomed Mater.* 2014;31:135–144.

References

33. Hampton C, Weitzler L, Baral E, Wright TM, Bostrom MPG. Do oxidized zirconium heads decrease tribocorrosion in total hip arthroplasty? A study of retrieved components. *Bone Joint J.* 2019;101-B:386–389.
34. Pawar V, Jones B, Sprague J, Salehi A, Hunter G. Acidic fretting tests of oxidized Zr-2.5Nb, CoCr and SS femoral heads. *ASM International.* 2005:403–408.
35. Cartner J, Aldinger P, Li C, Collins D. Characterization of femoral head taper corrosion features using a 22-year retrieval database. *HSS J.* 2016;13:35–41.
36. Papannagari R, Hines G, Sprague J. Wettability analysis of orthopaedic materials using optical contact angle methods. Poster presented at: ORS 2011 Annual Meeting; Long Beach, California, USA.
37. Hunter G and Long M. Abrasive wear of oxidized Zr-2.5Nb, CoCrMo, and Ti-6Al-4V against bone cement. Presented at: 6th World Biomaterials Cong. Trans., Society For Biomaterials; 2000; Minneapolis, MN.
38. Sugano N, Takao M, Sakai T, Nishii T, Miki H. Does CT-Based navigation improve the long-term survival in ceramic-on-ceramic THA? *Clin Orthop Relat Res.* 2012;470:3054–3059.
39. Davis ET, McKinney KD, Kamali A, Kuljaca S, Pagkalos J. Reduced risk of revision with computer-guided versus non-computer-guided THA. An analysis of manufacturer-specific data from the National Joint Registry of England, Wales, Northern Ireland and the Isle of Man. *JBJS OA.* 2021;6:e21.00006.
40. National Joint Registry for England, Wales and Northern Ireland: Polarstem Cementless implant summary report. 8 November 2023. Copy available from Smith & Nephew on request.
41. National Joint Registry for England, Wales and Northern Ireland: R3 Cementless Cup implant summary report. 8 November 2023. Copy available from Smith & Nephew on request.
42. Cypres A, Fiquet A, Girardin P, et al. Long-term outcomes of a dual-mobility cup and cementless triple-taper femoral stem combination in total hip replacement: a multicenter retrospective analysis. *J Orthop Surg Res.* 2019;14:376.
43. Yeroushalmi D, Singh V, Maher N, Gabor JA, Zuckerman JD, Schwarzkopf R. Excellent mid-term outcomes with a hemispheric titanium porous-coated acetabular component for total hip arthroplasty: 7–10 year follow-up. *Hip Int.* 2021 Aug 19 doi: 10.1177/11207000211040181.
44. Assaf A, Manara JR, Teoh KH, Evans AR. Mid-term clinical results of the cementless R3 cup and Polarstem total hip arthroplasty. *Eur J Orthop Surg Traumatol.* 2019;29:827–833.
45. Peters RM, Van Steenberg LN, Stevens M, Rijk PC, Bulstra SK, Zijlstra WP. The effect of bearing type on the outcome of total hip arthroplasty. *Acta Orthop.* 2018;89:163–169.
46. Duncan S, Patel A, Delhougne G, Patrick C. Can the choice of cementless implants and bearings during total hip arthroplasty have an impact on the overall costs within a bundled payment model? *J Hip Surg.* 2020;4:66–76.
47. Wade R, Shah KA. Functional and radiological outcome of uncemented total hip arthroplasty in young adults –5 year follow-up. *J Orthop.* 2019;18:237–239.
48. Ahmad A, Mirza Y, Evans A, Teoh K. A comparative study between uncemented and hybrid total hip arthroplasty in octogenarians. *J Arthroplasty.* 2018;33:3719–3723.
49. Gwynne-Jones D, Memon A. Acetabular liner dissociation: a comparative study of two contemporary uncemented acetabular components. *Arthroplast Today.* 2020;6:354–359.
50. Teoh KH, Whitham RDJ, Golding DM, Wong JF, Lee PYF, Evans AR. R3 cup does not have a high failure rate in conventional bearings: a minimum of 5-year follow-up. *J Arthroplasty.* 2018;33:460–463.
51. Patrick C, Delhougne G, Patel AR. Retrospective analysis of oxidized zirconium bearing surface in hip replacement 90-day episode claims. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR); May 18–22, 2019; New Orleans, Los Angeles, USA.
52. Alva A, Nizam I, Gogos S. Minimizing complications in bikini incision direct anterior approach total hip arthroplasty: a single surgeon series of 865 cases. *J Exp Orthop.* 2018;8:1.
53. Willburger RE, Heukamp M, Lindenlauv TE, Peterlein CD, Schuttler KF. Excellent midterm survival and functional outcomes of a fully hydroxyapatite-coated cementless stem: first results of a prospective multicenter study. *Arthroplast Today.* 2020;6:201–205.
54. Wilson AI, Turgeon TR, Gascoyne RW, Della Valle CJ, McCalden RW. Midterm results of a contemporary, porous-coated acetabular system in patients undergoing primary total hip replacement for degenerative hip disease: a prospective, multicenter study. *J Arthroplasty.* 2020;35:1862–1867.
55. Orthopaedic Data Evaluation Panel (ODEP). Available at <http://www.odep.org.uk>. Accessed December 8, 2023.
56. Fontalis A, Kayani B, Vanhegan I, Tahmassebi J, Haddad IC, Giebaly DE, Rajput V, Hansjee S, Haddad FS. 2-year radiostereometric analysis evaluation of a short, proximally coated, triple-taper blade femoral stem versus a quadrangular-taper stem with reinforced proximal body: a randomized controlled trial. *J Arthroplasty.* 2023;38(7S):S152–S161.
57. Shichman I, Lawrence KW, Berzolla E, Hernandez CS, Man-El R, Warschawski Y, Snir N, Schwarzkopf R, Heppinstall MS. Comparison of canal fill and radiolucent line formation between two fully coated, hydroxyapatite tapered stems: a 2-year follow-up after total hip arthroplasty. *Arch Orthop Trauma Surg.* 2023;143:6945–6954.
58. Kuroda Y, Hashimoto S, Hayashi S, Nakano N, Fujishiro T, Hiranaka T, Kuroda R, Matsumoto T. Study summary: Fully hydroxyapatite-coated compaction broached and triple-tapered stem may reduce the risk of stress shielding after primary total hip arthroplasty. *Arch Orthop Trauma Surg.* 2022;142:4087–4093.

Abbreviations and terminology

Abbreviations

ABT	Advanced bearing technology	HHS	Harris Hip Score
AOANJRR	Australian Orthopaedic Association National Joint Replacement Registry	HR	Hazard ratio
CI	Confidence interval	ISR	Implant summary report*
CMoXLPE	Ceramicised metal on XLPE	LOS	Length of stay
CoC	Ceramic on ceramic	LROI	Landelijke Registratie Orthopedische Implantaten (Dutch Arthroplasty Register)
CoXLPE	Ceramic on highly crosslinked polyethylene	MACC	Mechanically assisted crevice corrosion
CoPE	Ceramic on polyethylene	MoHXLPE	Metal on highly crosslinked polyethylene
CPCS	Collarless polished cemented stem	MoPE	Metal on polyethylene
CT	Computerised tomography	MoXLPE	Metal on crosslinked polyethylene
DAA	Direct anterior approach	NICE	National Institute for Health and Care Excellence
EQ-5D	EuroQol-5 Dimensions	NJR	National Joint Registry [†]
HAC	Hydroxyapatite coating	OA	Osteoarthritis

*ISRs are produced by the National Joint Registry of England, Wales and Northern Ireland and summarises usage and outcomes associated with the specific combinations of products. These analyses are based on data collected by the NJR and PROMs data collected by NHS Digital. Disclaimer relating to the use of ISRs: The data used for this analysis was obtained from the NJR Supplier Feedback System. The Healthcare Quality Improvement Partnership ('HQIP') and/or the National Joint Registry ('NJR') take no responsibility for the accuracy, currency, reliability and correctness of any data used or referred to in this report, nor for the accuracy, currency, reliability and correctness of links or references to other information sources and disclaims all warranties in relation to such data, links and references to the maximum extent permitted by legislation.

[†]We thank the patients and staff of all the hospitals in England, Wales and Northern Ireland who have contributed data to the National Joint Registry. We are grateful to the Healthcare Quality Improvement Partnership (HQIP), the NJR Steering Committee and staff at the NJR Centre for facilitating this work. The views expressed represent those of the authors and do not necessarily reflect those of the National Joint Registry Steering Committee or the Health Quality Improvement Partnership (HQIP) who do not vouch for how the information is presented.

*XLPE is classified as ultra-high molecular weight polyethylene that has been irradiated by high dose (>50kGy) gamma or electron beam radiation.

Abbreviations and terminology

Abbreviations

ODEP	Orthopaedic Data Evaluation Panel
OHS	Oxford Hip Score
OR	Odds ratio
PE	Polyethylene
PROM	Patient reported outcome measure
QoL	Quality of life
RI	Real intelligence
SNF	Skilled nursing facility
THA	Total hip arthroplasty
VAS	Visual analogue scale
WOMAC	Western Ontario and McMaster Universities Osteoarthritis Index

Terminology variations

Ceramic/Ceramic	Ceramic on ceramic
Ceramic/PE	Ceramic on polyethylene
Ceramic/XLPE	Ceramic on polyethylene
CMoXLPE or OXINIUM^o/XLPE	Ceramicised metal on XLPE
CPE	Conventional polyethylene
Metal/PE	Metal on polyethylene
Metal/XLPE	Metal on XLPE

For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.

Smith & Nephew, Inc
1450 Brooks Road
Memphis,
TN 38116,
USA

Smith & Nephew
Orthopaedics AG, Baar,
Switzerland is the legal
manufacturer for POLARCUP[◊]
and POLARSTEM[◊]

[◊]Trademark of Smith+Nephew
All Trademarks acknowledged
©2024 Smith+Nephew
22464 V6 0224. Published February 2024.

Developed by Evidence Communications,
Global Clinical & Medical Affairs
www.smith-nephew.com

Smith+Nephew